Pulmonary hypertension in 2012: Contemporary issues in diagnosis and management

Panminerva Medica

Volumn 54, Issue 1, 2012, Pages 11-28

  Lau, E M T ^a,b   Corte, T J ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Hypertension; Pulmonary ; Pulmonary arterial hypertension ; Vasodilator agents

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE; CLASSIFICATION; DRUG COMBINATION; DRUG EFFECT; EARLY DIAGNOSIS; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PULMONARY ARTERY; PULMONARY HYPERTENSION; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; HUMANS; HYPERTENSION, PULMONARY; PREDICTIVE VALUE OF TESTS; PULMONARY ARTERY; TREATMENT OUTCOME;

EID: 84858853407     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (130)

1. Galiè N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial metaanalyses. Eur Heart J 2010;31:2080-6.
2. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
3. Galie N, Palazzini M, Manes A. Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed. Eur Respir J 2010;36:986-90.
4. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54.
5. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119:2250-94.
6. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173:1027.
7. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619.
8. Saggar R, Khanna D, Furst DE, Shapiro S, Maranian P, Belperio JA et al. Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities. Arthritis Rheum 2010;62:3741-50.
9. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010;137:376-87.
10. Delcroix M, Spaas K, Quarck R. Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy. Eur Respir Rev 2009;18:253-9.
11. Kane GC, Maradit-Kremers H, Slusser JP, Scott CG, Frantz RP, McGoon MD. Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest 2011;139:1285-93.
12. Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-100. (Pubitemid 351902178)
13. Lau EM, Manes A, Celermajer DS, Galie N. Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward. Eur Heart J 2011.
14. Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest 2011;140:19-26.
15. Paleviky HI. The early diagnosis of pulmonary arterial hypertension: can we do better? Chest 2011;140:4-6.
16. Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007;37:485-94. (Pubitemid 46855082)
17. York M, Farber HW. Pulmonary hypertension: screening and evaluation in scleroderma. Curr Opin Rheumatol 2011;23:536-44.
18. Vachiery JL, Coghlan G. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2009;18:162-9.
19. Hesselstrand R, Ekman R, Eskilsson J, Isaksson A, Scheja A, Ohlin AK et al. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology (Oxford) 2005;44:366-71. (Pubitemid 40361295)
20. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:14S-34S. (Pubitemid 38932340)
21. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93. (Pubitemid 37323574)
22. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800. (Pubitemid 41798217)
23. Phung S, Strange G, Chung LP, Leong J, Dalton B, Roddy J et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 2009;39:682-91.
24. Humbert M, Nunes H, Sitbon O, Parent F, Herve P, Simonneau G. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001;22:459-75. (Pubitemid 32912079)
25. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-95. (Pubitemid 38252536)
26. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and longterm survival. Arthritis Rheum 2011;63:3522-30
27. Schreiber BE, Valerio CJ, Keir GJ, Handler C, Wells AU, Denton CP et al. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis Rheum 2011;63:3531-9
28. Bonderman D, Wexberg P, Martischnig AM, Heinzl H, Lang MB, Sadushi R et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur Respir J 2011;37:1096-103.
29. Rich JD, Shah SJ, Swamy RS, Kamp A, Rich S. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest 2011; 139:988-93.
30. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003;167:735-40. (Pubitemid 36801751)
31. Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009;179:615-21.
32. Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011;365:44-53.
33. Tolle JJ, Waxman AB, Van Horn TL, Pappagianopoulos PP, Systrom DM. Exercise-induced pulmonary arterial hypertension. Circulation 2008;118:2183-9.
34. Neije R. In defence of exercise stress tests for the diagnosis of pulmonary hypertension. Heart 2011;97:94-5.
35. Neije R, Melot C. Letter by Neije and Melot regarding article, "Exercise-induced pulmonary arterial hypertension". Circulation 2009;120:e283; author reply e4.
36. Oudiz RJ, Rubin LI. Exercise-induced pulmonary arterial hypertension: a new addition to the spectrum of pulmonary vascular diseases. Circulation 2008; 118:2120-1.
37. Collins N, Bastian B, Quiqueree L, Jones C, Morgan R, Reeves G. Abnormal pulmonary vascular responses in patients registered with a systemic autoimmunity database: Pulmonary Hypertension Assessment and Screening Evaluation using stress echocardiography (PHASE-I). Eur J Echocardiogr 2006;7:439-46. (Pubitemid 44645060)
38. Grunig E, Weissmann S, Ehlken N, Fijalkowska A, Fischer C, Fourme T et al. Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. Circulation 2009; 119:1747-57.
39. Steen V, Chou M, Shanmugam V, Mathias M, Kuru T, Morrissey R. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. Chest 2008;134:146-51. (Pubitemid 352008776)
40. Callejas-Rubio JL, Moreno-Escobar E, de la Fuente PM, Pérez LL, Fernández RR, Sánchez-Cano D et al. Prevalence of exercise pulmonary arterial hypertension in scleroderma. J Rheumatol 2008;35:1812-6.
41. Reichenberger F, Voswinckel R, Schulz R, Mensch O, Ghofrani HA, Olschewski H et al. Noninvasive detection of early pulmonary vascular dysfunction in scleroderma. Respir Med 2009; 103:1713-8.
42. Condliffe R, Kiely DG, Peacock AJ, Corns PA, Gibbs JS, Vrapi F et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151-7.
43. Steen VD, Champion H. Is exercise-induced pulmonary hypertension ready for prime time in systemic sclerosis? Int J Clin Pract Suppl 2011:1-3.
44. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009;34:888-94.
45. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403.
46. Chaouat A, Neije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008;32:1371 -85.
47. Guazzi M, Arena R. Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol 2010;7:648-59.
48. O'Callaghan DS, Savale L, Montani D, Jaïs X, Sitbon O, Simonneau G et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011;8:526-38.
49. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112:485-91. (Pubitemid 20100285)
50. Barst RJ, Rubin U, Long WA, McGoon MD, Rich S, Badesch DB et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
51. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin U, Wigley FM et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34. (Pubitemid 30149039)
52. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF et al. Effects of the dual endothelin- receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23. (Pubitemid 32971843)
53. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC et al. Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hyper- tension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4. (Pubitemid 34229650)
54. Galie N, Humbert M, Vachiéry JL, Vizza CD, Kneussl M, Manes A et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-502. (Pubitemid 34439066)
55. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ et al. for the AIR Study Group. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002;347:322-9. (Pubitemid 34815354)
56. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
57. Barst RJ, McGoon M, Mc Laughlin VV, Tapson V, Rich S, Rubin L et al. for the Beraprost Study Group. Bera- prost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2125.
58. Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension. 1 : A randomized, placebo-controlled, double- blind, crossover study. J Am Coll Cardiol 2004;43:1149-53. (Pubitemid 38452588)
59. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al. for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildena- fil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57. (Pubitemid 41653106)
60. Singh T, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo- controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151:851 .e1 -851 .e5.
61. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A et al. for the Bosentan Randomized Trial of Endothelin Antagonist Therapy. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114:48-54. (Pubitemid 44305274)
62. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA et al. for the Ambrisentan in Pulmonary Arterial Hypertension RDBP-CMESAG. Ambrisentan for the treatment of pulmonary arterial hyperten- sion. Results of the Ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, Efficacy (ARIES) Study 1 and 2. Circulation 2008; 117:3010-9.
63. Galie N, Brundage BH, Ghofranie HA, et al on behalf of the Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group- Tadalafil Therapy for Pulmonary Arterial Hypertension. Circulation 2009; 119:2894-903.
64. Jing ZC, Yu ZX, Shen JY, Wu BX, Xu KF, Zhu XY et al. for the Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2001,183:1723-9.
65. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-63.
66. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
67. Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A et al. Combination of bosentan with epoprostenol in pulmonary arterial hyperten sion: BREATHE-2. Eur Respir J 2004;24:353-9. (Pubitemid 39232254)
68. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-63. (Pubitemid 44924827)
69. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-30.
70. McLaughlin VV, Benza RL, Rubin LI, Channick RN, Voswinckel R, Tapson VF et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915-22.
71. Hoeper MM, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691-4. (Pubitemid 46331988)
72. Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA et al. for the Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2011;30:632-43.
73. Keogh A, Strange G, McNeil K, Williams TJ, Gabbay E, Proudman S et al. The bosentan patient registry: long-term survival in pulmonary arterial hypertension. Intern Med J 2011;41:227-34.
74. Sitbon O, Jais S, Savale L. Upfront Triple combination therapy of I.V. epoprostenol with oral bosentan and sildenafil in idiopathic and heritable pulmonary arterial hypertension. Am J Respir Crit Care Med2011;183:A5910.
75. Sandoval J, Rothman A, Pulido T. Atrial septostomy for pulmonary hypertension. Clin Chest Med 2001;22:547-60. (Pubitemid 32912086)
76. Kurzyna M, Dabrowski M, Bielecki D, Fijalkowska A, Pruszczyk P, Opolski G et al. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest 2007;131:977-83. (Pubitemid 46608695)
77. Sandoval J, Gaspar J, Peña H, Santos LE, Córdova J, Del Valle K et al. Effect of Atrial Septostomy on the Survival of Patients with Severe Pulmonary Arterial Hypertension. Eur Respir J 2011.
78. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009;53:1119-26.
79. Aronson D, Eitan A, Dragu R, Burger AJ. Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure. Circ Heart Fail 2011;4:644-50.
80. Mores DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000;102:1718-23.
81. Delgado JF, Conde E, Sánchez V, López-Ríos F, Gómez-Sánchez MA, Escribano P et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2005;7:1011-6. (Pubitemid 41443595)
82. Corte TJ, McDonagh TA, Wort SJ. Pulmonary hypertension in left heart disease: A review. Int J Cardiol 2011.
83. Meyer P, Filippatos GS, Ahmed MI, Iskandrian AE, Bittner V, Perry GJ, et al. Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Circulation 2010;121:252-8.
84. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134:44-54. (Pubitemid 27329022)
85. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002;85:195-7. (Pubitemid 35245980)
86. Anand I, McMurray J, Cohn JN, Konstam MA, NotterT, Quitzau K et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:347-54. (Pubitemid 38970011)
87. Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension-a multi-center randomized study. Cardiology 2008;109:273-80. (Pubitemid 351328923)
88. Tedford RJ, Hemnes AR, Russell SD, Wittstein IS, Mahmud M, Zaiman AL et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail 2008;1:213-9.
89. Lewis GD, Shah R, Shahzad K et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116:1555-62. (Pubitemid 47511419)
90. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011;124:164-74.
91. Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005;127:1531-6. (Pubitemid 46218776)
92. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007;30:715-21. (Pubitemid 351194832)
93. Corte TJ, Wort SJ, Gatzoulis MA, Macdonald P, Hansell DM, Wells AU. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax 2009;64:883-8.
94. Corte TJ, Wort SJ, Gatzoulis MA, Engel R, Giannakoulas G, Macdonald PM et al. Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur Respir J 2010;36:819-25.
95. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducoloné A et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. AmJ Respir Crit Care Med 2005; 172:189-94. (Pubitemid 40981192)
96. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93:391-8.
97. Corte T, Talbot S, Wort S, Wells A. Nocturnal desaturation is associated with pulmonary hypertension in patients with mild to moderate interstitial lung disease. Am J Respir Crit Care Med 2009;179:A4057
98. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:1084-90. (Pubitemid 37338937)
99. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-63.
100. Rich S, Rabinovitch M. Diagnosis and treatment of secondary (noncategory 1) pulmonary hypertension. Circulation 2008; 118:2190-9.
101. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:619-28.
102. King TE, Jr., Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:92-9.
103. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363:620-8.
104. Han MK, Bach D, Hagan P. Presence Of Right Ventricular Dysfunction Modifies Treatment Response To Sildenafil In The StepIPFTrial. Am J Respir Crit Care Med 2011;183:A5301.
105. Bonderman D, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Dunkler D, Taghavi S et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 2007;115:2153-8. (Pubitemid 46659067)
106. Kim NH. Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? Eur Respir Rev 2010;19:68-71.
107. Lang IM. Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options. Eur Respir Rev 2009;18:24-8.
108. Suntharalingam J, Treacy CM, Doughty NJ, Goldsmith K, Soon E, Toshner MR et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008;134:229-36.
109. Jais X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronic Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008;52:2127-34.
110. Thistlethwaite PA, Kaneko K, Madani MM, Jamieson SW Technique and outcomes of pulmonary endarterectomy surgery. Ann Thorac Cardiovasc Surg 2008;14:274-82.
111. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998;101:927-34. (Pubitemid 28125268)
112. Hoeper M, Barst R, Bourge R et al. Imatinib Improves Exercise Capacity and Hemodynamics at 24 Weeks as Add-on Therapy in Symptomatic Pulmonary Arterial Hypertension Patients: The IM-PRES Study. Chest 2011;140:A1045.
113. Ghofrani HA, Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Eur Respir Rev 2009;18:35-41.
114. Ghofrani HA, Hoeper MM, Halank M, Meyer FJ, Staehler G, Behr J et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010;36:792-9.
115. Waxman AB, Lawler L, Cornett G. Cicletanine for the treatment of pulmonary arterial hypertension. Arch Intern Med 2008; 168:2164-6.
116. Waxman AB, Lawler L. Cicletanine therapy is well tolerated in patients with advanced pulmonary arterial hypertension. Am J of Resp Critic Care Med 2009;179:A3353.
117. Morrison K, Ernst R, Hess P, Studer R, Clozel M. Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function. J Pharmacol Exp Ther 2010;335:249-55.
118. Simonneau G, Lang I, Torbicki A. Efficacy, Safety And Tolerability Of ACT-293987, A Novel Oral, Non-prostanoid, Prostaglandin 12 (IP) Receptor Agonist: Results From A Phase IIa Study In Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2010;181:A2515.
119. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111:1339-46. (Pubitemid 36554704)
120. Galie N, Boonstra A, Ewert R. Effects of inhaled Aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension. Am J of Resp Critic Care Med 2010;181:A2516.
121. Guilluy C, Eddahibi S, Agard C, Guignabert C, Izikki M, Tu L et al. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med 2009; 179:1151-8.
122. Mouchers KT, Schalij I, de Boer MA, Postmus PE, van Hinsbergh VW et al. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J 2010;36:800-7.
123. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005;91:391-2. (Pubitemid 40299237)
124. Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99:249-54.
125. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995;26:1581-5.
126. Handoko ML, de Man FS, AIlaart CP, Paulus WJ, Westerhof N, Vonk-Noordegraaf A. Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: lessons from the left heart. Eur Respir Rev 2010;19:72-82.
127. Okada M, Harada T, Kikuzuki R, Yamawaki H, Hara Y. Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats. J Pharmacol Sci 2009;111:193-200.
128. Rouleau JL, Kapuku G, Pelletier S, Gosselin H, Adam A, Gagnon C et al. Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway. Circulation 2001;104:939-44. (Pubitemid 32778047)
129. Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 2010;182:652-60.
130. Handoko ML, de Man F, van Ballegoij J. Chronic treatment with low-dose bisoprolol improves survival and cardiac function in experimental pulmonary arterial hypertension. Am J Resp Critic Care Med 2010;181:A4896.